The Day In Review: Pozen, Inc. Inks Pain Deal With AstraZeneca PLC

Published: Aug 02, 2006

August 2, 2006 -- Pozen out-licensed its new pain compound to AstraZeneca in a deal worth up to $375 million; GTC Biotherapeutics won European approval for ATryn; Salix received FDA approval for MoviPrep; Avant received a $21 million grant from the Gates Foundation for a cholera vaccine; Pain Thera and King Pharma began a Phase I test of a new abuse-resistant painkiller; ISTA Pharma in-licensed US rights to an allergic conjunctivitis drug; Gene Logic will reduce staffing in its Genomics Division by 80 positions; and GPC Biotech began a Phase II test of satraplatin. The Centient Biotech 200™ moved up 20.5 points to 3677.66, a gain of .56%. More details...

Back to news